Cyamemazine

Jump to: navigation, search
Cyamemazine
Cyamemazine.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral, IM, IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability10-70%
MetabolismHepatic
Elimination half-life10 hours
ExcretionUrine
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H21N3S
Molar mass323.46 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Cyamemazine

Articles

Most recent articles on Cyamemazine

Most cited articles on Cyamemazine

Review articles on Cyamemazine

Articles on Cyamemazine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cyamemazine

Images of Cyamemazine

Photos of Cyamemazine

Podcasts & MP3s on Cyamemazine

Videos on Cyamemazine

Evidence Based Medicine

Cochrane Collaboration on Cyamemazine

Bandolier on Cyamemazine

TRIP on Cyamemazine

Clinical Trials

Ongoing Trials on Cyamemazine at Clinical Trials.gov

Trial results on Cyamemazine

Clinical Trials on Cyamemazine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cyamemazine

NICE Guidance on Cyamemazine

NHS PRODIGY Guidance

FDA on Cyamemazine

CDC on Cyamemazine

Books

Books on Cyamemazine

News

Cyamemazine in the news

Be alerted to news on Cyamemazine

News trends on Cyamemazine

Commentary

Blogs on Cyamemazine

Definitions

Definitions of Cyamemazine

Patient Resources / Community

Patient resources on Cyamemazine

Discussion groups on Cyamemazine

Patient Handouts on Cyamemazine

Directions to Hospitals Treating Cyamemazine

Risk calculators and risk factors for Cyamemazine

Healthcare Provider Resources

Symptoms of Cyamemazine

Causes & Risk Factors for Cyamemazine

Diagnostic studies for Cyamemazine

Treatment of Cyamemazine

Continuing Medical Education (CME)

CME Programs on Cyamemazine

International

Cyamemazine en Espanol

Cyamemazine en Francais

Business

Cyamemazine in the Marketplace

Patents on Cyamemazine

Experimental / Informatics

List of terms related to Cyamemazine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class which was introduced by Theraplix in France in 1972 and later in Portugal as well.[1][2][3][4] It is used for the treatment of schizophrenia and, especially, for psychosis-associated anxiety, due to its unique anxiolytic efficacy.[5][6]

Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of dopamine, α1-adrenergic, H1, and mACh receptor antagonism,[7] it additionally produces potent blockade of several serotonin receptors, including 5-HT2A, 5-HT2C, and 5-HT7.[7][8][9][10] These actions have been implicated in cyamemazine's anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A),[7][8] and despite being classified as a typical, it actually behaves like an atypical antipsychotic.[11]

See also

References

  1. Index nominum, international drug ... - Google Books.
  2. David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 534. ISBN 0-412-46630-9.
  3. Pharmaceutical manufacturing ... - Google Books.
  4. Bret P, Bret MC, Queuille E (April 2009). "[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]". L'Encéphale (in French). 35 (2): 129–38. doi:10.1016/j.encep.2008.03.007. PMID 19393381.
  5. "Stahl's Essential Psychopharmacology - Cambridge University Press".
  6. Bourin M, Nic Dhonnchadha BA, Claude Colombel M, Dib M, Hascoët M (September 2001). "Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice". Behavioural Brain Research. 124 (1): 87–95. doi:10.1016/S0166-4328(01)00238-8. PMID 11423169.
  7. 7.0 7.1 7.2 Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology. 65 (3): 435–40. doi:10.1016/S0006-2952(02)01515-0. PMID 12527336.
  8. 8.0 8.1 Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology. 147 (4): 412–7. doi:10.1007/s002130050010. PMID 10672635.
  9. Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP (November 2002). "5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle". European Journal of Pharmacology. 454 (2–3): 235–9. doi:10.1016/S0014-2999(02)02489-5. PMID 12421652.
  10. Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A (January 2008). "Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes". European Journal of Pharmacology. 578 (2–3): 142–7. doi:10.1016/j.ejphar.2007.09.025. PMID 17936750.
  11. Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M (February 2003). "Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine". Naunyn-Schmiedeberg's Archives of Pharmacology. 367 (2): 134–9. doi:10.1007/s00210-002-0665-4. PMID 12595954.

Linked-in.jpg